MS Potential Therapy – This New Drug Reveals Incredible Potential
There’s good news for these people whose every day lives are overshadowed by the disease like MS. The race is lastly on to develop a more practical treatment for the disease between major drug manufactures. Merck has been in the process of testing their newest medicine Cladribine as a possible MS treatment. Their analysis has confirmed that sufferers who have undergone a short collection of treatments with this new oral drug have a very high rate of success in attaining decreased relapse rates when compared to most of the currently available medications for multiple sclerosis.
To emphasize the potential for Cladribine as a treatment for MS the manufacturer offered a report to the European Committee for Treatment and Research in Multiple Sclerosis Congress. The results they offered showed involved a research group consisting of sufferers who took one of 2 different doses or a placebo. The results confirmed that 43 and 44 per cent of these taking the drug were found to be symptom free for a period of 2 full years. This was compared to solely sixteen per cent of those that were given the placebo.
Merck is currently working hard with the FDA to gain approval whilst their rivals at Biogen and Novartis are creating mediations and looking for approval. The general potential for Cladribine as an MS treatment is slightly overshadowed by a very slight threat of cancer in some patients. Because this may be the primary oral treatment available for MS sufferers and as such may very well be a possible blockbuster for the manufacturer.
One of the biggest benefits of this medicine is for these in the late stage of multiple sclerosis are far less likely to end up being disabled. It has additionally been proven that this new drug might help to reduce the danger of lesions developing. In line with many neurologists the potential for Cladribine as an MS treatment far outweighs any recognized risks and in reality they are much more likely to prescribe this new drug for their sufferers in any part of the disease over the medicines being developed by either Novartis or Biogen.
No matter which set of tests you look at the numbers coming back show the particular potential of Cladribine as a treatment for MS. Sufferers who have waited years for a truly efficient treatment are anxiously awaiting approval of this new medicine and are praying that the FDA does not drag their feet. This is the primary new medicine to come along in many years to show this sort of potential and anticipation is high in both the medical community and sufferers alike.
Related Articles
